2019 was a critical year for the development of the robotics activity on the French market. Last April, Dedalus France created a Robotics division dedicated to launching Pharmoduct® on the French market. This division, led by Clarisse Fontaine, shows the group’s will to position itself strongly in France, on a market with high potential.

In a national context of increasing activity and mutualization of production units, a single healthcare institution may need to manufacture for other hospitals in the same Hospital Territorial Group (GHT). In line with this growth, a new approach must be found and robotization seems the most relevant response to productivity issues – while at the same time ensuring high preparation quality and therefore guaranteeing safety both for patients and for healthcare professionals.


Thanks to the work of Dedalus France’s sales teams, along with the expertise of the robotics division in France and in Italy (Bioduct), the first French reference for Pharmoduct® was signed last October with Poitiers University Hospital.

Poitiers University Hospital is recognized for its will to innovate and includes as part of this acquisition the Lead User Program, which is aimed at promoting collaboration with Dedalus for innovation in motion in the field of oncology pharmacy.

Poitiers University Hospital officially inaugurated Pharmoduct® on December 11th, 2019, at the Pôle Régional de Cancérologie (Regional Oncology Centre).

Among those present were:
  • Jean-Pierre Dewitte, Director General of Poitiers University Hospital
  • Frédéric Vaillant, CEO of Dedalus France
  • Jean-Marc Tourani, Head of the Oncology Center of Poitiers University Hospital
  • Alain Claeys, deputy mayor of Poitiers and Chair of the Supervisory Board of Poitiers University Hospital
  • Isabelle Princet, pharmacist and hospital practitioner at Poitiers University Hospital.

Jean-Pierre Dewitte highlights that “With the Pharmoduct robot, innovation serves safety and quality of care for our patients in oncology”.

Each year, over 53,000 chemotherapy preparations are administered to patients in the oncology center. ”Pharmoduct allows us to make the procedure safer and easier for our healthcare professionals – their job is repetitive, exhausting and causes musculoskeletal disorders”, adds Isabelle Princet. With Pharmoduct, the pharmacist mentions robotization of practices: “The robot does not operate at night or on weekends and does not replace humans. It assists professionals. The robot will absorb half the unit’s production”. This new technology allows to make treatments available faster to patients and also contributes to improving the working conditions of pharmacy technicians.

To follow up with this inauguration and in partnership with the Dedalus group’s robotics team, Poitiers University Hospital invited other healthcare institutions to come and view the robot and to see it demonstrated during the “Robotics Tuesdays” events (in French, “Mardis de la Robotique”).


Following this initial inauguration, a second French healthcare institution officialized its collaboration with Dedalus France for deploying Pharmoduct: Périgueux Hospital will start the robot installation process next May.

For the year 2020, market expectations and Dedalus France’s ambitions are up to the enthusiasm drawn by this innovative technology.